Frequently Asked Questions (pdf )

• Pharmacokinetics

• Pharmacodynamics

Literature

Publications

Using mammalian cell cycle simulation to interpret differential kinase inhibition in anti-tumour pharmaceutical development C Chassagnole, R.C. Jackson, N. Hussain, L. Bashir, C Derrow, J. Savin and D.A. Fell, BioSystems Volume 83, Issues 2-3, February-March 2006, pages 91-97. Reprint on request

Presentations (pdf )

Making better Cancer Therapies with Modelling Dr. Christophe Chassagnole, COO EPIC 2009, London, UK, 25 June 2009.

Systems Biology for Cancer Drug Development Dr. Christophe Chassagnole, COO BIO-Europe 2008, Mannheim/Heidelberg, Germany, 17-19 November 2008.

Optimal cancer chronotherapeutics schedules using a Systems Biology approach - Chronotherapeutics of Seliciclib Dr. Christophe Chassagnole, COO Beyond Genome Conference 2008, San Francisco, CA, 8-11 June 2008.

Systems Biology for Cancer Drug Development Dr Adam Hardy, Senior Simulation Scientist BioTrinity 2008 Oxford - Quadrangle at Kassam, Oxford, UK, 15-16 April 2008.

Drug Discovery and the New Biology Pr David A Fell, CSO Biotuesday – Milton Park, Abingdon, UK, 20 February 2007.

Devlopping Virtual Tumours for Reduced Attrition Physiomics plc Beyond Genome: Pathway and Disease Modeling, San Francisco, CA, 19-21 June 2006.

Posters (pdf )

Computer modelling of Nocodazole exposure on cell cultures in vitro E Fernandez, G Johnson, D Orrell, C Snell, DA Fell, SH Doak and C Chassagnole AACR-EORTC-NCI "Molecular Targets and Cancer Therapeutics", Boston, MA, 16 November 2009.

Chronotherapy: Seliciclib dosing schedules determined using a detailed computational cancer model AR Hardy, E Fernandez, C Snell, D Orrell, DA Fell and C Chassagnole AACR 100th Annual Meeting 2009, Denver, CO, 18-22 April 2009.

Optimal cancer chronotherapeutic schedules of Seliciclib revealed by a systems biology approach E Fernandez, A Hardy, D Orrell, L Ramsell, DA Fell and C Chassagnole AACR 2008, San Diego, CA, 12-16 April 2008.

Systems biology analysis of CYC116, a novel aurora kinase inhibitor C Chassagnole, E Fernandez, F Scaërou, C Snell, D Zheleva, DM Glover, RC Jackson, DA Fell AACR 2008, San Diego, CA, 12-16 April 2008.

Modelling DNA Damage-Induced Apoptosis A R Hardy, D Orrell, C M Snell, C Chassagnole, G Morris and D A Fell ICSB 2007, Long Beach, CA, 1-6 October 2007.

Virtual Tumour Modelling The Effect of Aurora Kinase Inhibitors on the Cell Cycle C Chassagnole, C M Snell, A R Hardy, A Finney, E Fernandez and D A Fell EBI, Cambridge, UK, 11-13 March 2007.

Cell Cycle Lab: using SystemCell® Technology for Multiple-Cell Simulations C Chassagnole, M Swat, C Derow, A Finney, C Snell, J Savin and DA Fell 6th International Conference on Systems Biology, October 2005, Boston.

Cell Cycle Simulations for Examining the Effects of Drugs Inhibiting Aurora Kinases According to Cancer Cell Phenotype C Chassagnole, M Swat, C Derow, A Finney, C Snell, J Savin and DA Fell 6th International Conference on Systems Biology, October 2005, Boston.

Patents

SystemCell Technology is a patented control system architecture covered by:

• US patent: 6,446,055 issued Sep 3 2002
• European Patent: 0937286

The priority date is November 5th 1996.

Physiomics is currently pursuing other patentable innovations relating to the pharmaceutical application of systems biology and SystemCell technology.

Back to the top